Janux Therapeutics Past Earnings Performance
Past criteria checks 0/6
Janux Therapeutics's earnings have been declining at an average annual rate of -34.1%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 50.3% per year.
Key information
-34.1%
Earnings growth rate
49.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 50.3% |
| Return on equity | -9.2% |
| Net Margin | -463.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause
Dec 03Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01
Janux Therapeutics: Buoyed By Buyout Speculation
Sep 01Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Revenue & Expenses Breakdown
How Janux Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 13 | -61 | 39 | 0 |
| 30 Jun 24 | 15 | -44 | 28 | 0 |
| 31 Mar 24 | 7 | -56 | 27 | 0 |
| 31 Dec 23 | 8 | -58 | 26 | 0 |
| 30 Sep 23 | 8 | -63 | 25 | 0 |
| 30 Jun 23 | 8 | -68 | 25 | 0 |
| 31 Mar 23 | 9 | -67 | 24 | 0 |
| 31 Dec 22 | 9 | -63 | 22 | 0 |
| 30 Sep 22 | 7 | -60 | 21 | 0 |
| 30 Jun 22 | 7 | -54 | 18 | 0 |
| 31 Mar 22 | 5 | -44 | 15 | 0 |
| 31 Dec 21 | 4 | -33 | 10 | 0 |
| 30 Sep 21 | 2 | -21 | 7 | 0 |
| 30 Jun 21 | 1 | -11 | 4 | 0 |
| 31 Mar 21 | 0 | -8 | 2 | 0 |
| 31 Dec 20 | 0 | -7 | 2 | 0 |
Quality Earnings: JANX is currently unprofitable.
Growing Profit Margin: JANX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JANX is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.
Accelerating Growth: Unable to compare JANX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JANX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: JANX has a negative Return on Equity (-9.23%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 16:15 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Janux Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Kaveri Pohlman | BTIG |
| Justin Zelin | BTIG |